UPDATE: New Phase 2 LILAC study results showed the investigational drug BIIB059, or litifilimab, significantly reduced lupus skin disease (cutaneous lupus erythematosus (CLE)) activity in 16 weeks of treatment compared to those who received placebo. Litifilimab is being explored for the treatment of lupus skin disease and lupus.
A group of 132 people with lupus skin disease were given one of four different doses of the drug or placebo to determine response. Over a period of 16 weeks, the researchers saw a significant improvement in skin disease activity level across litifilimab doses compared to placebo. Improvement was assessed by participants’ CLASI-A scores, a measure of skin disease activity.
Inside Lupus Research reported on the first part of the Phase 2 LILAC trial. More research is needed across larger groups and for longer periods of time to assess the effect and safety of the drug for CLE. Continue to follow the Lupus Foundation of America for updates on litifilimab and learn more about medications used to treat lupus.
This post was originally published on this site